Delving into the Latest Updates on JJGW08 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

5-HT1A receptor x 5-HT2A receptor x 5-HT7 receptor x D2 receptor

Mechanism

5-HT1A receptor antagonists(Serotonin 1a (5-HT1a) receptor antagonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT7 receptor antagonists(Serotonin 7 (5-HT7) receptor antagonists)

+ [1]

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Anxiety DisordersCognition DisordersMemory Disorders+ [1]

Inactive Indication-

Originator Organization

Uniwersytet Jagiellonski Collegium Medicum

Active Organization

Uniwersytet Jagiellonski Collegium Medicum

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Memory impairments constitute a significant problem worldwide, and the COVID-19 pandemic dramatically increased the prevalence of cognitive deficits. Patients with cognitive deficits, specifically memory disturbances, have underlying comorbid conditions such as schizophrenia, anxiety, or depression. Moreover, the available treatment options have unsatisfactory effectiveness. Therefore, there is a need to search for novel procognitive and anti-amnesic drugs with additional pharmacological activity. One of the important therapeutic targets involved in the modulation of learning and memory processes are serotonin receptors, including 5-HT_1A, 5-HT₆, and 5-HT₇, which also play a role in the pathophysiology of depression. Therefore, this study aimed to assess the anti-amnesic and antidepressant-like potential of JJGW08, a novel arylpiperazine alkyl derivative of salicylamide with strong antagonistic properties at 5-HT_1A and D₂ receptors and weak at 5-HT_2A and 5-HT₇ receptors in rodents. First, we investigated the compound's affinity for 5-HT₆ receptors using the radioligand assays. Next, we assessed the influence of the compound on long-term emotional and recognition memory. Further, we evaluated whether the compound could protect against MK-801-induced cognitive impairments. Finally, we determined the potential antidepressant-like activity of the tested compound. We found that JJGW08 possessed no affinity for 5-HT₆ receptors. Furthermore, JJGW08 protected mice against MK-801-induced recognition and emotional memory deficits but showed no antidepressant-like effects in rodents. Therefore, our preliminary study may suggest that blocking serotonin receptors, especially 5-HT_1A and 5-HT₇, might be beneficial in treating cognitive impairments, but it requires further investigation.

100 Deals associated with JJGW08

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Anxiety Disorders	Preclinical	-	Uniwersytet Jagiellonski Collegium Medicum	14 Dec 2022
Cognition Disorders	Preclinical	-	Uniwersytet Jagiellonski Collegium Medicum	14 Dec 2022
Memory Disorders	Preclinical	-	Uniwersytet Jagiellonski Collegium Medicum	14 Dec 2022
Psychotic Disorders	Preclinical	-	Uniwersytet Jagiellonski Collegium Medicum	14 Dec 2022